ICLR — ICON plc

Is ICLR overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Diagnostics & Research

Overbought As of August 19, 2026

ICON plc (ICLR) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Diagnostics & Research) last closed at $172.49. The rating moved from Oversold to Overbought on August 18, 2026.

See all overbought Healthcare stocks →

AI analysis

ICON plc benefits from secular growth in biologics and complex trials, a diversified sponsor base, and scale advantages that support steady revenue visibility and improving margins. Recent sector reads (gene‑therapy approvals and increased demand for specialized CDMO/CRO capacity) reinforce demand for ICON’s analytical and trial services. Near-term market conditions are neutral, limiting headline-driven volatility. Key upside drivers include backlog conversion, higher‑value service mix, and successful execution on operational efficiencies. Primary concerns are client timing, competitive pricing, FX and input cost pressures, and potential trial delays tied to regulatory or funding environments.

Key factors

  • Leading global CRO with diversified client base and established relationships across large pharma and biotech sponsors
  • Secular demand tailwinds from biologics, gene therapy, and complex trial modalities increasing need for specialized CRO/CDMO and analytical services
  • Recurring revenue profile from multi-year study contracts and high backlog visibility helps revenue predictability
  • Operational scale and geographic footprint enabling competitive advantages in large, global, multi-site clinical programs
  • Margin improvement opportunities from operational efficiencies, higher mix of specialized services, and potential pricing power for complex programs
  • Near-term market environment steady (limited macro surprises), allowing sponsor budgets and trial activity to continue without major disruption

Risks

  • Client concentration and potential delays/cancellations of large trials can materially impact near-term revenue
  • Pricing pressure and competition from other large CROs and specialized niche providers could compress margins
  • Regulatory, geopolitical, or trial-site disruptions (including pandemic resurgences or local regulatory slowdowns) that delay study timelines
  • Foreign exchange exposure and cost inflation (labor, site costs) that could pressure margins if not fully recovered in pricing
  • Execution risk integrating acquisitions or scaling specialized service lines (e.g., gene therapy analytics and viral-vector support)
  • Downturn in biotech funding or sponsor R&D budgets in a tighter capital market environment, reducing new study starts

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for ICLR — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.